Drug function
PHR-160 is as an activator of CFTR without influence on NBC1/AE although all of these transporters are commonly under the control of cAMP.
The heterologous regulation of these transporters possibly occurs due to cytoskeleton-dependent/cAMP-independent modulation of these anion transporters.
The unique effects of PHR-160 have, at least in part, the potential to ameliorate these lung diseases.
